Core Insights - BeOne Medicines AG (NASDAQ:ONC) is identified as one of the top 12 stocks to buy and hold for the next two years [1] Financial Performance - For Q4 2025, BeOne Medicines reported total global revenues of $1.5 billion, marking a 33% increase from the prior quarter and a 40% increase from the same quarter the previous year [2] - The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion in Q4 and $3.9 billion for the full year, reflecting growth of 38% and 49% respectively compared to prior periods [2] Analyst Ratings and Guidance - Following the earnings report, Truist Securities raised its price target for BeOne Medicines to $412 from $400 while maintaining a Buy rating [3] - Truist's fiscal 2026 revenue guidance for BeOne Medicines is set between $6.2 billion and $6.4 billion, which aligns closely with consensus estimates of $6.4 billion [4] - The current outlook suggests healthy growth for Brukinsa even without significant label expansions [4] Company Overview - BeOne Medicines AG is a global oncology company focused on discovering and developing innovative treatments that are more affordable and accessible for cancer patients worldwide [5]
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment